A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Zilebesiran (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms KARDIA-1
- Sponsors Alnylam Pharmaceuticals
- 01 Jul 2024 Planned End Date changed from 4 Dec 2024 to 5 Dec 2024.
- 08 Apr 2024 Results of subgroup analysis assessing zilebesiran efficacy and safety presented at the 73rd Annual Scientific Session of the American College of Cardiology
- 07 Apr 2024 According to an Alnylam Pharmaceuticals media release, results form subgroup from this trial were presented at the 2024 American College of Cardiology (ACC) Annual Scientific Session.